Evropská unie - čeština - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant může být použit jako monoterapie nebo v kombinaci s methotrexátem. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Evropská unie - čeština - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitida, atopická - ostatní dermatologické přípravky - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

pfizer, spol. s r.o., praha array - 9971 flukonazol - tvrdá tobolka - 100mg - flukonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

pfizer, spol. s r.o., praha array - 9971 flukonazol - tvrdá tobolka - 150mg - flukonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

pfizer, spol. s r.o., praha array - 9971 flukonazol - tvrdá tobolka - 50mg - flukonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

aurovitas, spol. s r.o., praha array - 9971 flukonazol - tvrdá tobolka - 100mg - flukonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

aurovitas, spol. s r.o., praha array - 9971 flukonazol - tvrdá tobolka - 150mg - flukonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

vitabalans oy, hämeenlinna array - 9971 flukonazol - tableta - 150mg - flukonazol